Clicky

ObsEva SA(OBSN)

Description: ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. The company is also involved in developing Ebopiprant, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, which is in Phase II clinical trial as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist that is in Phase I clinical trial to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. ObsEva SA was founded in 2012 and is headquartered in Geneva, Switzerland.


Keywords: Biopharmaceutical Drugs Pain Organic Compounds Chemical Compounds Ethers Endometriosis Uterine Fibroid In Vitro Fertilization Gnrh Antagonists Pyrimidines Oxytocin Preterm Labor Triketones

Home Page: www.obseva.com

Chemin des Aulx, 12
Geneva, 1228
Switzerland
Phone: 41 22 552 38 40


Officers

Name Title
Mr. Brian O'Callaghan CEO & Director
Dr. Ernest Loumaye M.D., OB/GYN, Ph.D. Co-Founder & Director
Mr. Fabien Lefebvre de Ladonchamps Chief Admin. Officer
Mr. Clive Bertram Chief Commercial Officer
Mr. Luigi Marro Chief Transformation Officer
Mr. William Michael Brown Chief Financial Officer
Ms. Delphine Renaud Personal Assistant to the CSO and Head of R&D
Ms. Katja Buhrer Chief Strategy Officer
Ms. Brandi Howard Ph.D. Chief Clinical Officer

Exchange: SW

Country: CH

Currency: Swiss Franc (CHF)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.727
Price-to-Sales TTM: 3.8338
IPO Date:
Fiscal Year End: December
Full Time Employees: 48
Back to stocks